The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2020 | Acalabrutinib monotherapy in mature B-cell malignancies
Richard Furman
• 10 Jun 2020
Richard Furman, MD, of the Weill Cornell Medical College, New York, NY, discusses the safety of acalabrutinib monotherapy in mature B-cell malignancies and goes on to discuss the long-term follow-up of efficacy data. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
